NextPlat (NXPL) Other financing activities (2011 - 2024)

NextPlat's (NXPL) quarterly Other financing activities came in at $122000.0 in Q1 2024, up 124.11% quarter-over-quarter from -$506000.0 in Q4 2023.

Analysis

NextPlat (NXPL) Other financing activities (2011 - 2024) Analysis & Trends

NextPlat (NXPL) has reported Other financing activities for 4 consecutive years, with $122000.0 the latest figure, recorded in Q1 2024.

On a quarterly basis, Other financing activities changed N/A year-over-year to $122000.0 in Q1 2024; TTM through Dec 2024 was $122000.0, a 33.7% decrease from a year earlier, with the FY2024 full-year figure at $122000.0, down 33.7% from the prior year.
Other financing activities was $122000.0 for Q1 2024 at NextPlat, up from -$506000.0 in the prior quarter.
Over five years, Other financing activities peaked at $4.6 million in Q3 2021 and troughed at -$506000.0 in Q4 2023.
A 3-year average of $821756.5 and a median of $153000.0 in 2023 frame the typical range for Other financing activities.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	42.34 Bn	38.68 Bn	2.15 Bn
2	Viatris	19.39 Bn	18.50 Bn	1.46 Bn
3	Dr Reddys Laboratories	9.99 Bn	9.85 Bn	396.53 Mn
4	Amneal Pharmaceuticals	5.57 Bn	5.53 Bn	334.51 Mn
5	Bausch Health Companies	2.45 Bn	1.58 Bn	2.10 Bn
6	Ani Pharmaceuticals	1.70 Bn	1.34 Bn	165.89 Mn
7	Alvotech	1.66 Bn	1.52 Bn	2.56 Mn
8	Amphastar Pharmaceuticals	985.90 Mn	695.77 Mn	93.47 Mn
9	Fennec Pharmaceuticals	434.07 Mn	392.82 Mn	17.15 Mn
10	NextPlat	24.77 Mn	12.93 Mn	4.69 Mn

Historic Data

Download Data